Investors & Media

Investor Relations Home

Corporate Profile The Medicines Company is focused on advancing the treatment of critical care patients through the delivery of innovative, cost-effective medicines to the worldwide hospital marketplace. The Company markets Angiomax® (bivalirudin) in the United States and other countries for use in patients undergoing coronary angioplasty, and Cleviprex® (clevidipine butyrate) injectable emulsion in the United States for the reduction of blood pressure when oral therapy is not feasible or not desi... More >>

Stock Quote MDCO (Common Stock) Exchange NASDAQ (US Dollar) Price $7.41 Change (%)   0.11 (1.46%) Volume 153,871 Data as of 02/08/10 4:00 p.m. ET Minimum 20 minute delay Refresh quote

Date Title   01/15/10 The Medicines Company Announces Option Grants Under NASDAQ Marketplace Rule 5635 PARSIPPANY, NJ, Jan 15, 2010 (MARKETWIRE via COMTEX) -- The Medicines Company (NASDAQ: MDCO) announced today that in accordance with NASDAQ Marketplace Rule 5635, the Company issued new inducement stock options to five new hires. The inducement stock options cover 6,000 shares of common stock and are classified as non-qualified stock options with an exercise price equal to the fair market value on the grant date. The options have a 10-year term and vest over four years as follows: 25 percent o...  01/05/10 The Medicines Company to Participate in the 28th Annual JP Morgan Healthcare Conference PARSIPPANY, NJ, Jan 05, 2010 (MARKETWIRE via COMTEX) -- The Medicines Company (NASDAQ: MDCO) will present at the 28th Annual JP Morgan Healthcare Conference on Tuesday, January 12th, in San Francisco, beginning at 2:30pm Pacific Standard Time, 5:30pm Eastern Standard Time. Clive A. Meanwell, Chairman and Chief Executive Officer, will provide a company overview and outlook in the presentation. The session will be webcast with a link available at The Medicines Company's website http://www.themed...  01/04/10 The Medicines Company Files Additional Patent Infringement Lawsuits PARSIPPANY, NJ, Jan 04, 2010 (MARKETWIRE via COMTEX) -- The Medicines Company (NASDAQ: MDCO) today announced that it has filed lawsuits against Teva Parenteral Medicines, Inc., Pliva Hrvatska d.o.o. and related entities in the United States District Court for the District of Delaware alleging patent infringement based on Abbreviated New Drug Applications seeking U.S. Food and Drug Administration approval to market and sell generic versions of The Medicines Company's Angiomax(R) product prior to ...  12/22/09 / CORRECTION -- The Medicines Company Acquires ApoA-I Milano From Pfizer PARSIPPANY, NJ and NEW YORK, NY, Dec 22, 2009 (MARKETWIRE via COMTEX) -- In the news release, "The Medicines Company Acquires ApoA-I Milano From Pfizer," issued earlier today by The Medicines Company (NASDAQ: MDCO), we are advised by the company that the Domestic Dial In number for the Wednesday, December 23 conference call should be 866-825-1709 rather than 866-285-1709 as originally issued. Complete corrected text follows. The Medicines Company Acquires ApoA-I Milano From Pfizer Produ...

Receive E-mail Alerts

Sign up to receive e-mail alerts whenever The Medicines Company posts new information to the site. Just enter your e-mail address and click Submit.

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.